Inogen, Inc. INGN lowered its 2026 revenue outlook after second-quarter results showed continued U.S. channel pressure despite better profitability and international growth. The revision puts more focus on how quickly the company can adapt its commercial model.
The key question is whether weaker direct sales and rentals mainly reflect a channel transition or a more persistent growth constraint. International demand, new products and cost control provide offsets, but execution remains important.
Inogen’s Guidance Cut Resets 2026 Expectations
Inogen now expects 2026 revenues of $355 million to $361 million, down from its previous $366 million to $373 million range. The revised midpoint implies about 3% growth from 2025.
For the third quarter, management expects revenues to be roughly in line with the year-earlier period. The outlook reflects U.S. sales-channel mix pressure and the timing of select international distributor inventory purchases.
Image Source: Zacks Investment Research
INGN’s U.S. Channel Shift Drives the Pressure
The U.S. oxygen market is moving more rapidly toward portable oxygen concentrators, or POCs, as the initial therapy supplied by home medical equipment providers. That reduces the pool of patients who historically later approached Inogen directly for a portable alternative.
Second-quarter U.S. sales fell 2.3% year over year to $42.3 million, while U.S. rental revenues declined 11.8% to $11.6 million. Inogen is expanding its business-to-business effort, but direct-to-consumer pressure is expected to continue in the second half.
Inogen’s International Business Provides an Offset
International sales rose 14.8% year over year to $41.3 million in the second quarter, marking the 10th consecutive quarter of double-digit growth. Geographic expansion and deeper distributor relationships support the longer-term international strategy.
Near-term order patterns may be uneven. Management expects several distributors to manage inventories during the second half because of factors including delayed tenders and distributor consolidation, which could shift purchase timing.
INGN’s New Products Could Broaden Growth
Inogen has shipped more than 5,000 Voxi stationary oxygen concentrators, while Aurora CPAP mask customers more than doubled sequentially in the second quarter. These products extend the company beyond POCs while using many of the same home medical equipment relationships.
Image Source: Zacks Investment Research
Resmed Inc. RMD operates across sleep and breathing health with care delivered in the home, highlighting the overlap between respiratory and sleep markets. Inspire Medical Systems, Inc. INSP focuses on obstructive sleep apnea through implantable neurostimulation, another approach to sleep-related respiratory care.
Inogen’s Profitability Trend Offers Support
Adjusted gross margin improved 65 basis points year over year to 45.6% in the second quarter, helped by cost improvements and lower warranty expenses. Adjusted operating loss narrowed to $1.3 million from $2.6 million a year earlier.
Management is reviewing its cost structure to align spending with strategic priorities. That discipline could support profitability while Inogen invests in business-to-business selling, product development, clinical programs and international expansion.
Image Source: Zacks Investment Research
INGN’s Signals Reflect Mixed Near-Term Conditions
The lower revenue outlook leaves Inogen balancing international growth and product expansion against a structural shift in its U.S. direct and rental channels. Near-term progress depends on whether business-to-business gains can offset continued direct-channel erosion.
INGN currently carries a Zacks Rank #3 (Hold), with a VGM Score of C, Value Score of C, Growth Score of D and Momentum Score of A. The Rank points to a neutral short-term earnings-revision backdrop, while the Style Scores show favorable momentum but weaker growth characteristics and middling value and combined readings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Style Scores are designed to complement the Zacks Rank, so the combination does not provide a uniformly positive or negative signal. The coming quarters should offer clearer evidence on channel adaptation, distributor timing and contributions from newer respiratory products.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.